Comparable endemic coronavirus nucleoprotein-specific antibodies in mild and severe Covid-19 patients
Artikel i vetenskaplig tidskrift, 2021
The severity of disease of Covid-19 is highly variable, ranging from asymptomatic to critical respiratory disease and death. Potential cross-reactive immune responses between SARS-CoV-2 and endemic coronavirus (eCoV) may hypothetically contribute to this variability. We herein studied if eCoV nucleoprotein (N)-specific antibodies in the sera of patients with mild or severe Covid-19 are associated with Covid-19 severity. There were comparable levels of eCoV N-specific antibodies early and during the first month of infection in Covid-19 patients with mild and severe symptoms, and healthy SARS-CoV-2-negative subjects. These results warrant further studies to investigate the potential role of eCoV-specific antibodies in immunity to SARS-CoV-2 infection.
nucleoprotein‐specific antibodies
COVID‐19
endemic coronaviruses
disease severity
Författare
Susannah Leach
Göteborgs universitet
Sahlgrenska universitetssjukhuset
Ali M. Harandi
Göteborgs universitet
University of British Columbia (UBC)
Tomas Bergstrom
Göteborgs universitet
Lars-Magnus Andersson
Göteborgs universitet
Sahlgrenska universitetssjukhuset
Staffan Nilsson
Göteborgs universitet
Chalmers, Matematiska vetenskaper, Tillämpad matematik och statistik
Lia van der Hoek
Universiteit Van Amsterdam
Magnus Gisslen
Göteborgs universitet
Sahlgrenska universitetssjukhuset
Journal of Medical Virology
0146-6615 (ISSN) 1096-9071 (eISSN)
Vol. 93 9 5614-5617Ämneskategorier
Infektionsmedicin
Gastroenterologi
Reumatologi och inflammation
DOI
10.1002/jmv.27038
PubMed
33913546